IIPR

In November 2025, IIPR's stock rose by 5.6% due to the emergence of marijuana consumption lounges but later declined by 5.4% due to challenges in its cannabis-focused portfolio. In March 2026, the stock saw fluctuations, including rises of 6.8% and 5.4% attributed to positive details from its 2025 financial results and a new 2026 Omnibus Incentive Plan, but also declined by 5.1% due to a perceived gap between projected earnings and market valuation. In April 2026, the federal rescheduling of medical cannabis to Schedule III eliminated the 280E tax burden for cannabis operators. In early May 2026, IIPR reported Q1 2026 results with revenue of $69.0 million, surpassing estimates, and significant leasing activity, driving shares up by 13% despite a year-over-year revenue decrease and EPS miss. The company maintained its quarterly dividend of $1.90 per common share and is addressing a $300 million bond maturity in May 2026 through capital-raising initiatives.